D. Pareyson, P. Saveri, and C. Pisciotta, New developments in Charcot-Marie-Tooth neuropathy and related diseases, Curr. Opin. Neurol, vol.30, pp.471-480, 2017.

H. Skre, Genetic and clinical aspects of Charcot-Marie-Tooth disease, Clin. Genet, vol.6, pp.98-118, 1974.

V. Fridman, The international CMT consortium, J. Neurol. Neurosurg. Psychiatry, vol.86, pp.873-878, 2015.

G. Manfioletti, M. E. Ruaro, G. Sal, L. Philipson, and C. Schneider, A growth arrest-specific (gas) gene codes for a membrane protein, Mol. Cell Biol, vol.10, pp.2924-2930, 1990.

S. Sancho, P. Young, and U. Suter, Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A, Brain, vol.124, pp.2177-2187, 2001.

C. Brancolini, P. Edomi, S. Marzinotto, and C. Schneider, Exposure at the cell surface is required for gas3/PMP22 to regulate both cell death and cell spreading: Implication for the Charcot-Marie-Tooth type 1A and Dejerine-Sottas diseases, Mol. Biol. Cell, vol.11, pp.2901-2914, 2000.

E. Fabbretti, P. Edomi, C. Brancolini, and C. Schneider, Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: Its relation to the demyelinating peripheral neuropathy CMT1A, Gene. Dev, vol.9, pp.1846-1856, 1995.

C. Huxley, E. Passage, A. Manson, D. Putzu, J. F. Figarella-branger et al., Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA, Hum. Mol. Genet, vol.5, pp.563-569, 1996.

M. Sereda, I. Griffiths, A. Puhlhofer, H. Stewart, M. J. Rossner et al., A rat transgenic model for Charcot-Marie-Tooth disease, Neuron, vol.16, pp.1049-1060, 1996.

J. P. Magyar, R. Martini, T. Ruelicke, A. Aguzzi, K. Adlkofer et al., Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage, J. Neurosci, vol.16, pp.5351-5360, 1996.

S. Mones, B. Bordignon, and M. Fontés, Connexin 32 is involved in mitosis, Glia, vol.60, pp.457-464, 2012.

V. Boczonadi, M. J. Jennings, and R. Horvath, The role of tRNA synthetases in neurological and neuromuscular disorders, FEBS Lett, vol.592, pp.703-717, 2018.

S. Züchner, I. V. Mersiyanova, M. Muglia, N. Bissar-tadmouri, J. Rochelle et al., Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A, Nat. Genet, vol.36, pp.449-451, 2004.

H. Chen, S. A. Detmer, A. J. Ewald, E. E. Griffin, S. E. Fraser et al., Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development, J. Cell Biol, vol.160, pp.189-200, 2003.

H. Chen, A. Chomyn, and D. C. Chan, Disruption of fusion results in mitochondrial heterogeneity and dysfunction, J. Biol. Chem, vol.280, pp.26185-26192, 2005.

A. Niemann, M. Rueegg, V. La-padula, A. Schenone, and U. Suter, Ganglioside-induced differentiation associated protein 1 (GDAP1) is a regulator of the mitochondrial network-New implications for Charcot-Marie-Tooth disease, J. Cell Biol, vol.170, pp.1067-1078, 2005.

A. Cuesta, L. Pedrola, T. Sevilla, J. García-planells, M. J. Chumillas et al., The gene encoding ganglioside-induced differentiation associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4Adisease, Nat. Genet, vol.30, pp.22-25, 2002.

R. V. Baxter, K. Ben-othmane, J. M. Rochelle, J. E. Stajich, C. Hulette et al., Ganglioside-induced differentiation associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21, Nat. Genet, vol.30, pp.21-22, 2002.

K. P. Giese, R. Martini, G. Lemke, P. Soriano, and M. Schachner, Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons, Cell, vol.71, pp.565-576, 1992.

R. Martini, J. Zielasek, K. V. Toyka, K. P. Giese, and M. Schachner, Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies, Nat. Genet, vol.11, pp.281-286, 1995.

L. E. Warner, P. Mancias, I. J. Butler, C. M. Mcdonald, L. Keppen et al., Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies, Nat. Genet, vol.18, pp.382-384, 1998.

S. Britsch, D. E. Goerich, and D. Riethmacher, The transcription factor Sox10 is a key regulator of peripheral glial development, Genes Dev, vol.15, pp.66-78, 2001.

P. Topilko, S. Schneider-maunoury, G. Levi, A. Baron-van-evercooren, A. B. Chennoufi et al., Krox-20 controls myelination in the peripheral nervous system, Nature, vol.371, pp.796-799, 1994.

E. Passage, J. C. Norreel, P. Noack-fraissignes, V. Sanguedolce, J. Pizant et al., Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease, Nat. Med, vol.10, pp.396-401, 2004.

M. W. Sereda, G. Meyer-zu-hörste, U. Suter, N. Uzma, and K. A. Nave, Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nat. Med, vol.9, pp.1533-1537, 2003.

H. T. Zhao, S. Damle, K. Ikeda-lee, S. Kuntz, J. Li et al., PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models, J. Clin. Investig, vol.128, pp.359-368, 2018.

S. Mones, B. Bordignon, F. Peiretti, J. F. Landrier, B. Gess et al., CamKII inhibitors reduce mitotic instability, connexon anomalies and progression of the invivo behavioral phenotype in transgenic animals expressing a mutated Gjb1gene, Front Neurosci, vol.13, pp.8-151, 2014.

S. Mones, B. Gess, B. Bordignon, A. Altié, P. Young et al., Fontes, M. CMTX11 patients' cells present genomic instability corrected by CamKII inhibitors, Orphanet J. Rare Dis, vol.10, 2015.

A. Kagiava, C. Karaiskos, J. Richter, C. Tryfonos, G. Lapathitis et al., Intrathecal gene therapy in mouse models expressing CMT1X mutations, Hum. Mol. Genet, vol.27, pp.1460-1473, 2018.

I. Das, A. Krzyzosiak, K. Schneider, L. Wrabetz, M. Antonio et al., Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit, Science, vol.348, pp.239-242, 2015.

J. Groh and R. Martini, Neuroinflammation as modifier of genetically caused neurological disorders of the central nervous system: Understanding pathogenesis and chances for treatment, vol.65, pp.1407-1422, 2017.

B. Corrado, G. Ciardi, and C. Bargigli, Rehabilitation Management of the Charcot-Marie-Tooth Syndrome: A Systematic Review of the Literature, Medicine, vol.95, p.3278, 2016.